

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
Search PubMed for [] Go Clear
Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

☐ 1: Lab Invest. 1998 Aug;78(8):967-72.

[Related Articles, Links](#)

Entrez PubMed

Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services

Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources

Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress collagen accumulation in experimental glomerulonephritis.

Sunamoto M, Kuze K, Tsuji H, Ohishi N, Yagi K, Nagata K, Kita T, Doi T.

Department of Clinical Bio-Regulatory Science, Faculty of Medicine, Kyoto University, Japan.

Heat shock protein 47 (HSP47) is a collagen-specific molecular chaperone that has been shown to play a major role during the biosynthesis and secretion of procollagen molecules. The expression of HSP47 has been reported to increase in parallel with the expression of collagens during the progression of various fibrosis models. However, it remains unclear whether an inhibition of HSP47 overexpression would suppress collagen accumulation and thus reduce the progression of fibrotic diseases. In this study, we attempted to attenuate glomerular collagen accumulation by inhibiting the overexpression of HSP47 with antisense oligodeoxynucleotides in an experimental glomerulonephritis model induced by anti-Thy-1 antibodies. The administration of antisense oligodeoxynucleotides against HSP47 at the induction of the glomerular disease markedly suppressed the increased production of collagens and attenuated the histologic manifestations of the disease. These results provide direct evidence of a pivotal role for HSP47 in the pathogenesis of glomerulonephritis.

PMID: 9714184 [PubMed - indexed for MEDLINE]


Display Abstract Show: 20 Sort Send to Text

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Bi
 Search PubMed for Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

☐ 1: Kidney Int Suppl. 1997 Dec;63:S232-5.

Related Articles, Links

Entrez PubMed

Overview
 Help | FAQ
 Tutorial
 New/Noteworthy
 E-Utilities

PubMed Services

Journals Database
 MeSH Database
 Single Citation Matcher
 Batch Citation Matcher
 Clinical Queries
 LinkOut
 Cubby

Related Resources

Order Documents
 NLM Gateway
 TOXNET
 Consumer Health
 Clinical Alerts
 ClinicalTrials.gov
 PubMed Central

TCV-116 inhibits interstitial fibrosis and HSP47 mRNA in rat obstructive nephropathy.

Moriyama T, Kawada N, Akagi Y, Ando A, Horio M, Yamauchi A, Nagata K, Imai E, Hori M.

First Department of Medicine, Osaka University School of Medicine, Faculty of Health, Japan. toshiki@medone.med.osaka-u.ac.jp

Unilateral ureteral obstruction (UO) is a well established disease model leading to fibrosis of the obstructed kidney. In this model, involvement of enhanced renin-angiotensin system in the pathogenesis of interstitial fibrosis has been demonstrated. A 47-kDa heat-shock protein (HSP47) was originally identified as a collagen-binding stress protein, and is currently considered to be a collagen-specific molecular chaperone that plays a pivotal role during the biosynthesis and secretion of procollagen from endoplasmic reticulum. To test if HSP47 is involved in interstitial fibrosis in UO, we examined the expression of HSP47 mRNA in rat UO kidneys after 12 hours, 1, 4, 7 days of obstruction. HSP47 mRNA expression was significantly increased as early as 12 hours after obstruction and was sustained at the increased level until seven days. Type I collagen mRNA significantly increased after four days of UO. Fibrotic changes of interstitium appeared in Masson's trichrome stained section after four days. To explore the possible involvement of angiotensin II (Ang II) in HSP47 induction, the effect of Ang II receptor antagonist (TCV-116) and angiotensin converting enzyme inhibitor (lisinopril) was tested. TCV-116 or lisinopril was given to the animals orally once a day at the dose of 10 mg/kg. TCV-116 or lisinopril significantly ameliorated the fibrotic change of interstitium seven days after obstruction. HSP47 and type I collagen mRNA levels in the TCV-116- or lisinopril-treated groups were reduced to about 60% of untreated UO. A possible involvement of HSP47 in the pathogenesis of interstitial fibrosis in UO is suggested; however, further investigation is required to identify the signals involved in the induction of HSP47 in UO.

PMID: 9407468 [PubMed - indexed for MEDLINE]



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Bo

Search PubMed for [] Preview Go Cle

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.
- Click on query # to add to strategy

Search

Most Recent Queries

Time Result

#6 Related Articles for PubMed (Select 8900930)	18:11:40	199
#4 Search hsp47 AND antibody	18:04:33	28
#3 Search hsp47	18:04:11	208
#1 Search hum. mol. genet.[jour] AND 4[volume] AND 2033[page] AND 1995[pdat] Field: Title Word	17:38:02	1

Clear History

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Aug 30 2004 06:52:01